Workup of Encephalopathy in Patients Receiving Cancer Immunotherapy
Seminars in Neurology · 30.10.2026
DOI: 10.1055/a-2979-5558 ↗Kurz gefasst
Fachartikel in der Zeitschrift Seminars in Neurology, online erschienen am 30.10.2026. Verfasst von Neil Sielski. Beteiligte Einrichtung: NYU Langone Health, Brain & Spine Tumor Center, New York, United States, New York. Die Arbeit nennt 72 Literaturangaben.
Abstract (Originalsprache)
Cancer immunotherapy has transformed many areas of oncologic care. Neurological immune-related adverse events, particularly encephalopathy, represent potentially life-threatening complications requiring prompt recognition and intervention. Encephalopathic syndromes occur across immunotherapy modalities, including immune checkpoint inhibitors, chimeric antigen receptor-T cell therapy, and bispecific antibodies. The diagnostic challenge lies in distinguishing immune-mediated neurotoxicity from infection, metabolic derangements, disease progression, and paraneoplastic syndromes. A systematic evaluation incorporates detailed clinical assessment with neuroimaging, cerebrospinal fluid analysis, electroencephalography, and autoimmune antibody testing as appropriate. This review provides a practical approach to recognizing and assessing encephalopathy in patients receiving immunotherapy. Early multidisciplinary collaboration between neurology and oncology teams is critical for recognizing symptoms, managing adverse effects, and guiding cancer-directed treatment.
Autor:innen und Institutionen
- NYU Langone Health, Brain & Spine Tumor Center, New York, United States, New York.
ORCID-Profile: Neil Sielski
Zitieren
APA
Sielski, N. (2026). Workup of Encephalopathy in Patients Receiving Cancer Immunotherapy. Seminars in Neurology. https://doi.org/10.1055/a-2979-5558
Vancouver
Sielski N. Workup of Encephalopathy in Patients Receiving Cancer Immunotherapy. Seminars in Neurology. 2026. doi:10.1055/a-2979-5558
BibTeX
@article{Sielski2026,
author = {Sielski, Neil},
title = {Workup of Encephalopathy in Patients Receiving Cancer Immunotherapy},
journal = {Seminars in Neurology},
year = {2026},
doi = {10.1055/a-2979-5558}
}
EUVIMED